Provided by Tiger Fintech (Singapore) Pte. Ltd.

ArTara Therapeutics, Inc.

4.31
+0.29007.21%
Post-market: 4.310.00000.00%16:05 EDT
Volume:150.73K
Turnover:643.12K
Market Cap:158.47M
PE:-1.99
High:4.37
Open:4.12
Low:4.10
Close:4.02
Loading ...

Company Profile

Company Name:
ArTara Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
31
Office Location:
345 Park Avenue South,3rd Floor,New York,New York,United States
Zip Code:
10010
Fax:
- -
Introduction:
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

Directors

Name
Position
Timothy P. Noyes
President, Chief Executive Officer and Director
Garen Bohlin
Director
Hubert Birner
Director
John G. Freund
Director
Jonathan Leff
Director
Paul J. Hastings
Director
Scott A. Canute
Director
Stuart A. Kingsley
Director
Tim Haines
Director

Shareholders

Name
Position
Timothy P. Noyes
President, Chief Executive Officer and Director
E. Scott Toner
Senior Vice President, Marketing
George A. Eldridge
Senior Vice President, Chief Financial Officer, Treasurer and Assist. Secretary
Steven K. Burke
Senior Vice President and Chief Medical Officer
Daniel P. Gottlieb
Vice President, Corporate Development
Matthew P. Kowalsky
Vice President, Legal and Secretary